Flag of the European Union EU Clinical Trials Register Help

Clinical trials for (cancer AND (Immunotherapy OR vaccine))

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,002 result(s) found for: (cancer AND (Immunotherapy OR vaccine)). Displaying page 18 of 51.
    «« First « Previous 14  15  16  17  18  19  20  21  22  Next» Last»»
    EudraCT Number: 2017-001683-37 Sponsor Protocol Number: PRODIGE55 Start Date*: 2018-04-04
    Sponsor Name:Fédération Francophone de Cancérologie Digestive
    Full Title: SecOnd-line Chemotherapy with RAmucirumab +/- pacliTaxel in Elderly advanced gastric or gastroesophageal junction cancer patients
    Medical condition: Elederly patient with advanced gastric or gastroesophageal junction cancer, after first line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10042080 Stomach cancer LLT
    20.0 100000004864 10042088 Stomach cancer stage IV with metastases LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005971-17 Sponsor Protocol Number: H8K-MC-JZAG Start Date*: 2007-03-27
    Sponsor Name:ELI LILLY
    Full Title: A Phase 2 Study of LY573636 as Treatment for Patients with Platinum-Resistant Ovarian Cancer Protocol H8K-MC-JZAG
    Medical condition: patients with epithelial ovarian cancer who have received no more than 2 prior systemic treatment regimens for platinum-resistant disease.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061328 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004784-12 Sponsor Protocol Number: HE1/17 Start Date*: 2018-04-16
    Sponsor Name:Hellenic Cooperative Oncology Group (HeCOG)
    Full Title: Phased Avelumab combined with chemotherapy as first-line treatment for patients with advanced small-cell lung cancer (SCLC)
    Medical condition: Advanced small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004413-13 Sponsor Protocol Number: DIRECT Start Date*: 2021-05-18
    Sponsor Name:Amsterdam UMC, VU University Medical Center
    Full Title: Dual-immunotherapy and short-course medium-dose radiotherapy, followed by surgery for tumor microenvironment modification in early stage NSCLC
    Medical condition: early stage non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004005-16 Sponsor Protocol Number: D081KC00001 Start Date*: 2016-03-01
    Sponsor Name:Astra Zeneca AB
    Full Title: A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Olaparib (PARP inhibitor) in Patients with Advanced Solid Tumors
    Medical condition: Initial stage cohort: SCLC germline BRCA mutated (gBRCAm) metastatic human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC) gBRCAm platinum sensitive relapsed ovarian cancer (O...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    21.1 100000004864 10071114 Metastatic gastric adenocarcinoma LLT
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    21.1 100000004864 10041071 Small cell lung cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003003-35 Sponsor Protocol Number: 2019_41 Start Date*: 2020-05-15
    Sponsor Name:CHU de LILLE
    Full Title: THE IMMUNOTHERAPY PLEURAL 5-ALA PDT “IMPALA” trial: Intrapleural Photodynamic Therapy by Video-Assisted Thoracoscopy followed by Anti-PD-1 NIVOLUMAB in Patients with Malignant Pleural Mesothelioma-...
    Medical condition: Pilot study of the feasibility of an innovative multimodal treatment combining intrapleural photodynamic therapy with videothoracoscopy followed by adjuvant immunotherapy with anti-PD-1 Nivolumab a...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005487-22 Sponsor Protocol Number: A2A-005 Start Date*: 2022-12-21
    Sponsor Name:iTeos Belgium SA
    Full Title: A randomized, double-blind, placebo-controlled, Phase 2 study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with nonsquamous non-small cell ...
    Medical condition: Nonsquamous non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) PL (Completed) DE (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005427-10 Sponsor Protocol Number: 1200.261 Start Date*: 2016-04-29
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: Phase II open label single arm exploratory trial of oral afatinib monotherapy following platinum failure for patients with advanced/metastatic urothelial tract carcinoma with ERBB receptor deregula...
    Medical condition: patients with advanced/metastatic urothelial tract carcinoma with ERBB receptor deregulation
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-005428-99 Sponsor Protocol Number: 08/0365 Start Date*: 2009-10-19
    Sponsor Name:University College London
    Full Title: A randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of bacillus Calmette-Guerin or standard therapy in patients with recurrence of non-muscle invasive b...
    Medical condition: Non muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005006 Bladder cancer stage 0, with cancer in situ LLT
    9.1 10005007 Bladder cancer stage 0, without cancer in situ LLT
    9.1 10005008 Bladder cancer stage I, with cancer in situ LLT
    9.1 10005009 Bladder cancer stage I, without cancer in situ LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004941-33 Sponsor Protocol Number: A6191007 Start Date*: 2006-03-02
    Sponsor Name:PFIZER
    Full Title: A Phase 2 Study of the Efficacy and Safety of SU-014813 in Patients with Metastatic Breast Cancer
    Medical condition: Locally Recurrent or Metastatic Breast Cancer MBC
    Disease: Version SOC Term Classification Code Term Level
    6.1 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001114-19 Sponsor Protocol Number: IB2022-01 Start Date*: 2023-04-03
    Sponsor Name:Institut Bergonié
    Full Title: Lurbinectedin combined with durvalumab (MEDI 4736) in pre-treated patients with extensive stage small-cell lung cancer
    Medical condition: platinum sensitive extensive stage small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002872-42 Sponsor Protocol Number: D9100C00001 Start Date*: 2019-02-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherap...
    Medical condition: Patient with FIGO Stages IB2 to IIB Node+ and IIIA to IVA with any node. Patients must not have previously received any definitive surgical, radiation, or systemic therapy for cervical cancer and m...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-002556-41 Sponsor Protocol Number: TRX 1.0 Start Date*: 2008-02-07
    Sponsor Name:Trimed Biotech GmbH
    Full Title: A randomized, open-label, 2-arm, multicentre, Phase II study to evaluate the safety and efficacy of Trivax, a dendritic cell-based interleukin-12 secreting autologous cancer vaccine, in combination...
    Medical condition: Metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-009885-15 Sponsor Protocol Number: LAP112620 Start Date*: 2009-08-27
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination with Vinorelbine or Capecitabine in Women with ErbB2 Overexpressing Metastatic Breast Cancer
    Medical condition: Breast Cancer (with ErbB2 Overexpressing Metastatic Breast Cancer)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) IT (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-005170-10 Sponsor Protocol Number: COMBI-TED Start Date*: 2021-04-30
    Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT)
    Full Title: A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-line therapy in metastatic non-small-cell lung cancer progr...
    Medical condition: metastatic non-small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062042 Lung neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003449-14 Sponsor Protocol Number: GO41836 Start Date*: 2020-07-14
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE FOLLOWING ADJUVANT PLATINUM-DOUBLET CHEMOTHE...
    Medical condition: Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005110-34 Sponsor Protocol Number: ICT01-102 Start Date*: 2022-02-08
    Sponsor Name:ImCheck Therapeutics, Inc.
    Full Title: A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advance...
    Medical condition: Relapsed/refractory patients with advanced solid tumors : metastatic colorectal cancer (CRC) or metastatic ovarian cancer or metastatic castration-resistant prostate cancer (mCRPC) or metastatic pa...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000288-18 Sponsor Protocol Number: I3Y-MC-JPCG Start Date*: 2016-07-21
    Sponsor Name:Lilly S.A.
    Full Title: A Randomized, Open-Label, Phase 2 Study of Abemaciclib plus Tamoxifen or Abemaciclib Alone, in Women with Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) AT (Completed) BE (Completed) DE (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004812-24 Sponsor Protocol Number: INCB39110-203 Start Date*: 2014-11-04
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non–Small Cell Lung Cancer
    Medical condition: Male or female, 18 years or older with histologically or cytologically confirmed diagnosis of NSCLC that is Stage IIIb, IV, or recurrent.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended) ES (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000458-20 Sponsor Protocol Number: 108160 Start Date*: 2017-11-14
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A post-marketing surveillance (PMS) study to monitor the safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ human papillo-mavirus (HPV) vaccine (Cervarix) in 3,000 healthy female Filip...
    Medical condition: Healthy volunteers (active immunization against Human papillomavirus infection in female subjects for the prevention of cervical cancer).
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 14  15  16  17  18  19  20  21  22  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 17 06:53:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA